Workflow
医药电商
icon
Search documents
众生药业涨2.19%,成交额1.57亿元,主力资金净流出216.00万元
Xin Lang Cai Jing· 2025-09-18 02:14
Company Overview - Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan, Guangdong Province, established on December 31, 2001, and listed on December 11, 2009. The company focuses on the research, production, and sales of pharmaceuticals [1]. - The main business revenue composition includes: Traditional Chinese Medicine sales 53.03%, chemical drug sales 38.12%, Chinese medicinal materials and decoction pieces sales 6.13%, raw materials and intermediates sales 2.14%, and others 0.58% [1]. Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%. However, the net profit attributable to the parent company was 188 million yuan, showing a significant year-on-year increase of 114.96% [2]. - Since its A-share listing, the company has distributed a total of 2.019 billion yuan in dividends, with 502 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 18, the stock price of Zhongsheng Pharmaceutical increased by 2.19%, reaching 20.54 yuan per share, with a total market capitalization of 17.458 billion yuan [1]. - The stock has seen a year-to-date increase of 71.88%, with a recent 5-day increase of 1.68%, a 20-day decrease of 8.95%, and a 60-day increase of 36.48% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 29, where it recorded a net purchase of 181 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per person, an increase of 1.33% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 9.1731 million shares, while other notable shareholders include Xingquan He Feng Mixed Fund and Xingquan Multi-Dimensional Value Mixed Fund, which have reduced their holdings [3].
振东制药跌2.12%,成交额2.02亿元,主力资金净流出2507.85万元
Xin Lang Cai Jing· 2025-09-17 07:02
Company Overview - Shanxi Zhendong Pharmaceutical Co., Ltd. is located in Changzhi City, Shanxi Province, and was established on November 15, 1995. The company went public on January 7, 2011. Its main business includes the research, production, and sales of generic and innovative drugs related to oncology, hair, digestion, urology, and cardiovascular diseases, as well as a full industry chain for traditional Chinese medicine [2]. Financial Performance - For the first half of 2025, Zhendong Pharmaceutical achieved operating revenue of 1.457 billion yuan, a year-on-year decrease of 3.30%. The net profit attributable to the parent company was 7.9313 million yuan, down 74.13% year-on-year [2]. - The company has cumulatively distributed 3.372 billion yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Stock Market Activity - As of September 17, Zhendong Pharmaceutical's stock price was 7.38 yuan per share, with a market capitalization of 7.419 billion yuan. The stock has increased by 70.83% year-to-date but has seen a decline of 4.28% in the last five trading days and 13.99% in the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on August 11, where it recorded a net purchase of 86.6539 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 46,100, a decrease of 5.04% from the previous period. The average circulating shares per person increased by 5.31% to 21,777 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 7.9704 million shares, an increase of 5.0578 million shares from the previous period [3].
大参林涨2.09%,成交额8637.18万元,主力资金净流入382.50万元
Xin Lang Cai Jing· 2025-09-17 06:55
Core Viewpoint - Dazhonglin's stock price has shown a positive trend this year, with a notable increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and investor interest [2][3]. Group 1: Stock Performance - As of September 17, Dazhonglin's stock price increased by 2.09% to 17.58 CNY per share, with a trading volume of 86.37 million CNY and a turnover rate of 0.43%, resulting in a total market capitalization of 20.02 billion CNY [1]. - Year-to-date, Dazhonglin's stock has risen by 19.19%, with a 1.62% increase over the last five trading days, a 2.33% increase over the last 20 days, and a 9.53% increase over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Dazhonglin achieved a revenue of 13.52 billion CNY, representing a year-on-year growth of 1.33%, while the net profit attributable to shareholders was 798 million CNY, reflecting a year-on-year increase of 21.38% [2]. - Since its A-share listing, Dazhonglin has distributed a total of 3.36 billion CNY in dividends, with 1.62 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, Dazhonglin had 31,500 shareholders, a decrease of 10.07% from the previous period, with an average of 36,097 circulating shares per shareholder, an increase of 11.20% [2]. - The fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 90.45 million shares, which is an increase of 12.43 million shares compared to the previous period [3].
新天药业跌2.06%,成交额5834.82万元,主力资金净流出643.57万元
Xin Lang Cai Jing· 2025-09-17 05:51
Company Overview - Xintian Pharmaceutical Co., Ltd. is located in Guizhou Province, established on August 11, 1995, and listed on May 19, 2017. The company specializes in the research, production, and sales of traditional Chinese medicine [1] - The main business revenue composition includes gynecological products (74.16%), urological products (17.04%), heat-clearing and detoxifying products (7.79%), and others (1.01%) [1] Stock Performance - As of September 17, the stock price of Xintian Pharmaceutical decreased by 2.06%, trading at 11.41 CNY per share, with a total market capitalization of 2.785 billion CNY [1] - Year-to-date, the stock price has increased by 21.72%, but it has seen a decline of 0.35% over the last five trading days and a 16.53% drop over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on August 20, where it recorded a net purchase of 56.32 million CNY [1] Financial Performance - For the first half of 2025, Xintian Pharmaceutical reported a revenue of 358 million CNY, a year-on-year decrease of 18.88%, and a net profit attributable to shareholders of 5.77 million CNY, down 80.99% year-on-year [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 61.87 million CNY distributed over the past three years [3] Shareholder Information - As of September 10, the number of shareholders decreased to 33,700, a reduction of 5.83%, while the average circulating shares per person increased by 6.19% to 7,083 shares [2] - As of June 30, 2025, the top ten circulating shareholders included a new entry, Nuoan Multi-Strategy Mixed A, holding 1.0731 million shares, while Baodao Yuanhang Mixed A exited the top ten list [3]
维康药业跌2.02%,成交额6744.97万元,主力资金净流出289.42万元
Xin Lang Cai Jing· 2025-09-17 02:52
9月17日,维康药业(维权)盘中下跌2.02%,截至10:30,报23.32元/股,成交6744.97万元,换手率 1.97%,总市值33.77亿元。 资料显示,浙江维康药业股份有限公司位于浙江省丽水经济开发区遂松路2号,成立日期2000年3月31 日,上市日期2020年8月24日,公司主营业务涉及现代中药及西药的研发、生产和销售。主营业务收入 构成为:中西成药97.16%,其他(补充)2.84%。 维康药业所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:肝炎治疗、抗流感、医药电 商、中药、小盘等。 截至6月30日,维康药业股东户数9892.00,较上期减少12.06%;人均流通股14569股,较上期增加 13.71%。2025年1月-6月,维康药业实现营业收入1.15亿元,同比减少61.42%;归母净利润-6421.97万 元,同比减少552.50%。 分红方面,维康药业A股上市后累计派现1.79亿元。近三年,累计派现5540.00万元。 责任编辑:小浪快报 资金流向方面,主力资金净流出289.42万元,大单买入795.25万元,占比11.79%,卖出1084.67万元,占 比16.08%。 维 ...
振东制药跌2.13%,成交额1.13亿元,主力资金净流出2859.85万元
Xin Lang Zheng Quan· 2025-09-16 02:46
9月16日,振东制药盘中下跌2.13%,截至10:39,报7.35元/股,成交1.13亿元,换手率1.51%,总市值 73.89亿元。 资料显示,山西振东制药股份有限公司位于山西省长治市上党区光明南路振东科技园,成立日期1995年 11月15日,上市日期2011年1月7日,公司主营业务涉及肿瘤、毛发、消化、泌尿、心脑等仿制药、创新 药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。主营 业务收入构成为:中药54.82%,化药43.10%,其他1.98%,销售材料0.10%,研发收入0.00%。 资金流向方面,主力资金净流出2859.85万元,特大单买入0.00元,占比0.00%,卖出555.02万元,占比 4.93%;大单买入1634.09万元,占比14.51%,卖出3938.91万元,占比34.98%。 振东制药所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:抗流感、维生素、医药电 商、肝炎治疗、幽门螺杆概念等。 截至6月30日,振东制药股东户数4.61万,较上期减少5.04%;人均流通股21777股,较上期增加5.31%。 2025年1月-6月,振东制药实现 ...
一品红跌2.06%,成交额1.24亿元,主力资金净流出1741.82万元
Xin Lang Cai Jing· 2025-09-16 02:41
9月16日,一品红盘中下跌2.06%,截至10:13,报60.93元/股,成交1.24亿元,换手率0.48%,总市值 275.22亿元。 资金流向方面,主力资金净流出1741.82万元,特大单买入259.43万元,占比2.10%,卖出703.22万元, 占比5.68%;大单买入1980.41万元,占比16.00%,卖出3278.45万元,占比26.48%。 一品红今年以来股价涨257.15%,近5个交易日跌11.13%,近20日跌14.83%,近60日涨19.56%。 一品红所属申万行业为:医药生物-化学制药-化学制剂。所属概念板块包括:抗流感、医药电商、肝炎 治疗、中药、猴痘概念等。 截至8月31日,一品红股东户数2.14万,较上期增加0.49%;人均流通股19553股,较上期减少0.49%。 2025年1月-6月,一品红实现营业收入5.84亿元,同比减少36.02%;归母净利润-7354.22万元,同比减少 258.30%。 分红方面,一品红A股上市后累计派现3.35亿元。近三年,累计派现1.51亿元。 机构持仓方面,截止2025年6月30日,一品红十大流通股东中,易方达医疗保健行业混合A(110023) ...
尔康制药涨2.12%,成交额1.19亿元,主力资金净流入889.51万元
Xin Lang Zheng Quan· 2025-09-15 06:04
Company Overview - Hunan Erkang Pharmaceutical Co., Ltd. is located in Changsha, Hunan Province, established on October 22, 2003, and listed on September 27, 2011. The company is engaged in the research, production, and sales of pharmaceutical products, primarily focusing on pharmaceutical excipients and new antibiotics [2]. Business Segmentation - The main business revenue composition includes: pharmaceutical excipients (36.29%), new energy materials (18.64%), composite excipients (16.21%), bulk excipients (14.62%), raw materials (6.88%), finished drugs (5.71%), and others (1.64%) [2]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 682 million yuan, representing a year-on-year growth of 9.74%. The net profit attributable to the parent company was 37.63 million yuan, showing a significant increase of 497.36% [2]. Stock Performance - As of September 15, the stock price of Erkang Pharmaceutical increased by 2.12%, reaching 3.85 yuan per share, with a trading volume of 119 million yuan and a turnover rate of 2.22%. The total market capitalization is 7.941 billion yuan [1]. - Year-to-date, the stock price has risen by 38.49%, with a slight decline of 0.52% over the last five trading days and a decrease of 5.64% over the last 20 days. However, it has increased by 24.19% over the last 60 days [1]. Shareholder Information - As of June 30, the number of shareholders reached 42,700, an increase of 4.40% from the previous period. The average circulating shares per person decreased by 4.22% to 33,275 shares [2]. - The company has distributed a total of 540 million yuan in dividends since its A-share listing, with cumulative distributions of 61.88 million yuan over the past three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the sixth-largest circulating shareholder, holding 21.56 million shares, an increase of 6.47 million shares compared to the previous period [3].
雅本化学涨2.04%,成交额7758.72万元,主力资金净流入387.09万元
Xin Lang Zheng Quan· 2025-09-15 05:16
Company Overview - Yabao Chemical Co., Ltd. is located in Taicang Port Development Zone, Jiangsu Province, and was established on January 13, 2006, with its listing date on September 6, 2011 [2] - The company specializes in the research, development, production, and sales of pesticide intermediates and pharmaceutical intermediates [2] - The revenue composition includes pesticide intermediates (69.58%), pharmaceutical intermediates (21.73%), other (4.15%), environmental products (2.85%), and specialty chemicals (1.70%) [2] Stock Performance - As of September 15, Yabao Chemical's stock price increased by 2.04% to 7.50 CNY per share, with a trading volume of 77.59 million CNY and a turnover rate of 1.12%, resulting in a total market capitalization of 7.23 billion CNY [1] - Year-to-date, the stock price has risen by 9.49%, with a recent 5-day increase of 0.27%, a 20-day decline of 6.37%, and a 60-day increase of 3.45% [2] Financial Performance - For the period from January to June 2025, Yabao Chemical achieved a revenue of 662 million CNY, representing a year-on-year growth of 12.31% [2] - The net profit attributable to shareholders was -8.67 million CNY, showing a year-on-year increase of 83.33% [2] Shareholder Information - As of August 31, the number of shareholders was 54,900, a decrease of 2.31% from the previous period, with an average of 17,045 circulating shares per shareholder, an increase of 2.36% [2] - The company has distributed a total of 478 million CNY in dividends since its A-share listing, with 95.90 million CNY distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 9.14 million shares as a new shareholder, while Southern CSI 1000 ETF has exited the top ten circulating shareholders [3]
珍宝岛跌2.05%,成交额4124.41万元,主力资金净流出652.15万元
Xin Lang Cai Jing· 2025-09-15 02:54
Core Points - The stock price of Zhenbao Island decreased by 2.05% on September 15, trading at 11.96 CNY per share with a total market capitalization of 11.254 billion CNY [1] - The company has seen a year-to-date stock price increase of 4.45%, with a recent 5-day increase of 0.93%, a 20-day decrease of 3.31%, and a 60-day increase of 7.46% [2] - Zhenbao Island's main business involves the research, production, and sales of high-end traditional Chinese medicine, with 84.82% of revenue coming from product sales [2] Financial Performance - For the first half of 2025, Zhenbao Island reported a revenue of 714 million CNY, a year-on-year decrease of 57.05%, and a net profit attributable to shareholders of -78.29 million CNY, a decrease of 119.90% [2] - The company has distributed a total of 1.302 billion CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3] Shareholder Information - As of July 18, Zhenbao Island had 21,500 shareholders, an increase of 2.34% from the previous period, with an average of 43,744 circulating shares per shareholder, a decrease of 2.29% [2]